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Abstract
 
Leukotriene B
 
4 
 
(LTB
 
4
 
) is a lipid mediator that activates leukocytes and is involved in host de-
fense and inflammation. BLT1, a high-affinity receptor for LTB
 
4
 
 (originally termed BLT), is
expressed exclusively in inflammatory cells and is inducible in macrophages upon activation.
The mechanisms of tissue-specific expression and induction of BLT1 are important for the un-
derstanding of mechanism of onset and the potential treatment of inflammatory disorders.
Here, we report the genomic structure and a promoter analysis of the human BLT1 gene, with
an emphasis on the mechanism of cell-specific transcription. No TATA or CAAT elements ex-
ist around the transcription initiation sites, but a GC-rich sequence is observed in this region. A
reporter gene assay revealed that a region 
 
z
 
80 basepair upstream from the initiator sequence is
required for the basal transcription of the BLT1 gene. Sp1 was found to be a major activator of
basal transcription by electrophoretic mobility shift assays and site-directed mutagenesis. The
CpG sites of the BLT1 promoter region were highly methylated in BLT1-nonexpressing cells,
but not methylated in BLT1-expressing cells. Further, methylation of this region in vitro in-
hibited the promoter activity to 
 
z
 
15% of the control. Thus, methylation at CpG sites in the
promoter region is important for cell-specific transcription of the BLT1 gene. The promoter
region of the BLT1 gene is localized within the open reading frame (ORF) of the BLT2 gene,
which encodes a low-affinity receptor for LTB
 
4 
 
(Yokomizo, T., K. Kato, K. Terawaki, T.
Izumi, and T. Shimizu. 2000. 
 
J. Exp. Med.
 
 192:421–431). To our knowledge, this is the first
example of “promoter in ORF” in higher eukaryotes.
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Introduction
 
Leukotriene B
 
4
 
 (LTB
 
4
 
),
 
1
 
 a metabolite of arachidonic acid,
is a potent lipid mediator. LTB
 
4
 
 mainly activates leuko-
cytes, leading to chemotaxis, degranulation, and produc-
tion of superoxide anions, thus playing important roles in
host defense (1, 2). LTB
 
4 
 
is also related to inflammatory
diseases such as rheumatoid arthritis (3), bronchial asthma
(4), psoriasis (5), ulcerative colitis (6), and postischemic tis-
sue injuries (7, 8). These actions of LTB
 
4
 
 are mediated by a
specific cell surface receptor, leukotriene B
 
4
 
 receptor
(BLT). Human BLT1 cDNAs were isolated (9, 10), and its
orthologues were obtained from mouse (11, 12), rat (13),
and guinea pig (14, 15). Human BLT1 mRNA is expressed
abundantly in leukocytes, and to a lesser degree in spleen
and thymus. In mice, BLT1 mRNA is abundant in eosino-
phils isolated from IL-5 transgenic mice and in activated
macrophages (11). Enhanced expression was also observed
in activated peritoneal macrophages in rats (13). Therefore,
the transcription of the BLT1 gene appears to be tightly
regulated in a cell- and tissue-specific manner, and is in-
ducible by various stimuli. To elucidate the mechanism of
the BLT1 expression, we analyzed the structure, promoter
region, and regulation of cell-specific transcription of the
human BLT1 gene. During the course of analysis of the
BLT1 gene, we identified a putative open reading frame
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(ORF) in the promoter region for a G protein–coupled re-
ceptor (GPCR) with structural similarity to BLT1. This re-
ceptor is revealed to be a low-affinity LTB
 
4
 
 receptor,
BLT2, which is reported in an accompanying paper (16).
 
Materials and Methods
 
Cell Culture and Isolation of Nucleic Acids.
 
THP-1 (human
monocytic leukemia cell line), U937 (human histiocytic lym-
phoma cell line), and HL-60 (human leukemia cell line) cells
were maintained in RPMI 1640 medium. HeLa (human cervical
cancer cell line) and HepG2 (human hepatoma–derived cell line)
cells were maintained in DME. All media were supplemented
with 10% fetal bovine serum, 100 IU/ml penicillin, and 100 
 
m
 
g/
ml streptomycin. Poly(A)
 
1
 
 RNA was isolated using a QuickPrep
Micro Purification Kit (Amersham Pharmacia Biotech). Genomic
DNA was isolated by treating cells with 200 
 
m
 
g/ml proteinase K
in the presence of 1 mM EDTA and 1% SDS, followed by phe-
nol extraction.
 
Isolation of the BLT1 Gene.
 
A human lymphocytes genomic
library (Stratagene) was screened by plaque hybridization with
the BLT1 ORF labeled with 
 
a
 
-[
 
32
 
P]dCTP. The positive ge-
nomic clone was subcloned into pBluescript SK(
 
2
 
)
 
 
 
and se-
quenced with an ABI 373 automated sequencer.
 
5
 
9
 
 Rapid Amplification of cDNA Ends Analysis.
 
5
 
9
 
 rapid ampli-
fication of cDNA ends (RACE) was performed using a 5
 
9
 
 RACE
System for Rapid Amplification of cDNA Ends (version 2.0; Life
Technologies). 1 
 
m
 
g of poly(A)
 
1
 
 RNA prepared from HL-60
cells differentiated by 1 
 
m
 
M retinoic acid for 48 h was used as a
template. First-strand cDNA was synthesized with the primer 1
(5
 
9
 
-GAACTCTACACCTAGTGAGG-3
 
9
 
 from 
 
1
 
48 to 
 
1
 
29
relative to the adenosine of first methionine; see Fig. 2 A). PCR
was performed using the primer 2 (5
 
9
 
-GTGCTGCAGAAGAT-
GTAGTG-3
 
9
 
 from 
 
1
 
25 to 
 
1
 
6) and the 5
 
9
 
 RACE Abridged
Anchor Primer (5
 
9
 
-GGCCACGCGTCGACTAGTACGGGI-
IGGGIIGGGIIG-3
 
9
 
; Life Technologies), followed by nested
PCR using the primer 3 (5
 
9
 
-TCCGGACCGTCCTTCTC-
CATCC from 
 
2
 
92 to 
 
2
 
113 relative to the adenosine of first
methionine in HL-5 clone) and the Abridged Universal Amplifi-
cation Primer (5
 
9
 
-GGCCACGCGTCGACTAGTAC-3
 
9
 
; Life
Technologies). PCR products were subcloned using an Original
TA Cloning Kit (Invitrogen), and were sequenced.
 
Reporter Gene Assay.
 
Various lengths of 5
 
9
 
 flanking regions of
the BLT1 gene were amplified by PCR using 20 mer of sense
and antisense primers. The KpnI and HindIII sites were added to
the 5
 
9 
 
ends of sense and antisense primers, respectively. These
amplified fragments were ligated into the KpnI–HindIII site of
the pGL3 basic vector (Promega) and sequenced, and we con-
firmed that there were no misincorporations by PCR. These 5
 
9
 
flanking region–firefly luciferase gene fusion plasmids (0.5 
 
m
 
g per
sample) were transfected into THP-1 (4 
 
3
 
 10
 
5
 
 cells per sample)
and HeLa cells (4 
 
3 
 
10
 
4
 
 cells per sample) using Effectene™
(QIAGEN). The plasmid, pRL-CMV (Promega; 0.1 
 
m
 
g per
sample) containing 
 
Renilla
 
 luciferase gene driven by the cytomeg-
alovirus immediate early enhancer/promoter was cotransfected,
and the luciferase activity was normalized. After incubation of the
cells at 37
 
8
 
C for 18 h, the luciferase assay was performed using a
Dual-Luciferase Reporter Assay System (Promega) and a lumi-
nometer (MiniLumat LB 9506; Berthold).
 
Electrophoretic Mobility Shift Assays.
 
Nuclear extracts were
prepared from THP-1 and HeLa cells by the method of Dignam
et al. (17). Nuclear extracts containing 5 
 
m
 
g of protein were in-
 
cubated in 20 
 
m
 
l of binding buffer (10 mM Tris-HCl pH 8.0, 50
mM NaCl, 1 mM MgCl
 
2, 
 
0.5 mM EDTA, 0.5 mM DTT, 50
 
m
 
g/ml poly(dI-dC) poly(dI-dC), and 4% glycerol) with or with-
out a cold competitor (a 200-fold molar excess). For supershift as-
says, 1 
 
m
 
g of anti-Sp1 antibody or rabbit IgG (Santa Cruz Bio-
technology, Inc.) was incubated at room temperature for 10 min.
The DNA probe (10,000 cpm) labeled with 
 
g
 
-[
 
32
 
P]ATP was
added, and the samples were incubated at room temperature for
20 min. Reaction mixtures were separated in a 4% polyacryla-
mide gel and autoradiographed to an X-ray film.
 
Site-directed Mutagenesis.
 
Mutagenesis of the putative Sp1 site
in p(
 
2
 
123/
 
1
 
91) was introduced using a QuikChange™ Site-
Directed Mutagenesis Kit (Stratagene) according to the manufac-
turer’s instructions. The primer used were MS-1 (5
 
9
 
-GCCTTG-
GCGAAGCTG
 
AA
 
C
 
A
 
GAGCCGGCCAGGCGG-3
 
9
 
, from 
 
2
 
66
to 
 
2
 
33 relative to the adenosine of the initiator sequence; muta-
tion sites are shown as bold letters in the primer sequence) and
MAS-1 (5
 
9
 
-CCGCCTGGCCGGCTC
 
T
 
G
 
TT
 
CAGCTTCGC-
CAAGGC-3
 
9
 
, from 
 
2
 
33 to 
 
2
 
66).
 
Genomic Southern Blot Analysis.
 
10 
 
m
 
g of genomic DNAs
were digested by HpaII or MspI, then digested by EcoRI. Reac-
tion mixtures were separated in 1% agarose gels and transferred to
Hybond N
 
1
 
 membranes (Amersham Pharmacia Biotech). The
membranes were incubated with 
 
a
 
-[
 
32
 
P]dCTP labeled DNA
probes (see Fig. 5 C) at 65
 
8
 
C overnight, and washed with 0.1
 
3
 
SSC, 0.1% SDS at 65
 
8
 
C. The washed membrane was autoradio-
graphed to an X-ray film.
 
Effect of Methylation at CpG Sites on the Promoter Activity.
 
20 
 
m
 
g
of the plasmid p(
 
2
 
123/
 
1
 
91) was digested by KpnI and HindIII,
and the insert was purified from a 2% agarose gel. This fragment
was incubated with or without SssI methylase (6 U/
 
m
 
g DNA;
New England BioLabs, Inc.) at the presence of 16 
 
m
 
M 
 
S
 
-adeno-
sylmethionine. After incubation at 37
 
8
 
C for 3 h, the DNA frag-
ment was ethanol precipitated, followed by ligation to the pGL3
basic vector at 16
 
8
 
C for 16 h. Aliquots of the ligated DNA were
ethanol precipitated and transfected into HeLa cells, and the lu-
ciferase assay was performed.
 
Results
 
Isolation of the BLT1 Gene.
 
z
 
10
 
6 
 
genomic
 
 
 
clones were
screened using the human BLT1 ORF as a probe, and we
obtained one positive clone (LambdaNOK) containing the
BLT1 gene. The map of this clone is shown in Fig. 1. The
human BLT1 gene is 
 
z5.5 kb in length and consists of
three exons. Most of the 59 untranslated region (UTR) of
either the HL-5 or HL-1 clone (10) is present on exon I
and exon II, respectively. The BLT1 ORF is found on
exon III, and is not interrupted by any introns. All the
exon/intron junctions obeyed the rule of GT/AG consen-
sus sequence (data not shown; 18).
59 RACE Analysis. When nested PCR was performed
using an oligonucleotide specific to the HL-5 sequence
(primer 3; Fig. 2 A), several amplified fragments were ob-
served (data not shown). Sequence analysis of these frag-
ments revealed three transcription initiation sites (Fig. 2 B,
asterisks). However, using a primer specific to the HL-1
clone, no specific fragment was observed (data not shown).
Nucleotide sequences of the putative promoter region
are shown in Fig. 2 B. One of the transcription initiation
sites is highly homologous to the initiator sequence415 Kato et al.
(YYA11NT/AYY, where Y is a pyrimidine nucleotide;
reference 19). Neither a TATA box nor a CAAT box was
observed near these transcription initiation sites, but a high
GC content was observed in this region. A search for bind-
ing sites for transcription factors revealed consensus se-
quences for NFkB (20), USF (21), AP-1 (22), AP-4 (23),
and Sp1 (reference 24; Fig. 2 B).
Promoter Activity and ORF in the Promoter Region. The
promoter activity was determined by transfecting the 59
flanking region–luciferase gene fusion plasmids to THP-1
and HeLa cells. THP-1 cells express BLT1, whereas HeLa
cells do not (see Fig. 5 D). Significant promoter activity
was observed in both cell lines transfected with the con-
structs containing the region between 21091 and 276 rel-
ative to the adenosine residue of the initiator sequence (Fig.
3). This activity was decreased markedly when the region
between 276 and 233 was deleted. No activity was de-
tected using p(24/191) in both cells. These results suggest
that the region from 276 to 233 is crucial for the basal
transcription of the BLT1 gene. Surprisingly, another ORF
homologous to BLT1 overlapped the promoter region.
This ORF was shown to encode the second receptor of
LTB4, which is described in detail in an accompanying pa-
per (16).
Electrophoretic Mobility Shift Assays and Site-directed Mu-
tagenesis. By luciferase assay, the region from 276 to 233
was found to be an important cis element in the basal tran-
scription of the BLT1 gene. Between 276 and 233, there
is a consensus sequence for Sp1 binding (Fig. 2 B). Electro-
phoretic mobility shift assay (EMSA) was performed to de-
termine whether Sp1 binds to this region. Several DNA–
protein complexes were observed in nuclear extracts of
both THP-1 and HeLa cells (Fig. 4 A, lanes 2 and 8). The
upper two bands disappeared when an excess of unlabeled
276/233 (a 200-fold molar excess) was added (Fig. 4 A,
lanes 3 and 9), showing that these bands are specific for this
region. However, an excess of oligonucleotide mutated at
this putative Sp1 binding site (59-GAACAG-39 at 252 to
247; mutation sites are shown as bold letters) did not com-
pete away the binding (Fig. 4 A, lanes 4 and 10). Coincu-
bation with anti-Sp1 antibody resulted in a supershift (Fig.
4 A, lanes 6 and 12), but control IgG did not give this re-
sponse (Fig. 4 A, lanes 5 and 11). These results show that
Sp1 binds to the GC box at 252/247 in the BLT1 pro-
moter region. Moreover, a lower band was supershifted
when an Sp3 antibody was coincubated (data not shown).
To investigate the effect of Sp1 binding in the promoter
activity, site-directed mutagenesis was performed. In both
THP-1 and HeLa cells, the luciferase activity of the mu-
tated construct was decreased to z25% of the wild-type
(Fig. 4 B). These results indicate that Sp1 binds to the
BLT1 promoter region and activates the basal transcription.
Methylation of CpG Sites in the Promoter Region. There
are many CpG sites surrounding the promoter region of
Figure 1. Genomic structure of the human BLT1 gene. The ORF
(light gray box), promoter region (dark gray box), and UTRs (open
boxes) of the BLT1 gene and the ORF of the BLT2 gene (hatched box)
are indicated. Restriction enzyme sites are indicated as follows: B,
BamHI; E, EcoRI; H, HindIII; K, KpnI; and S, SacI. These sequence
data (LambdaNOK) are available from EMBL/GenBank/DDBJ under
accession no. AB008193. Note that the BLT2 ORF is overlapped with
the BLT1 promoter region.
Figure 2. Identification of the transcription initiation site of the BLT1
gene. (A) The sites of primers used for 59 RACE are shown. Arrows indi-
cate the synthetic oligonucleotides. (B) Nucleotide sequences of the 59
flanking region of the BLT1 gene. Asterisks show the transcription initia-
tion sites determined by 59 RACE. GC boxes (consensus sequences of
Sp1) are shown in open boxes. The consensus sequences of various tran-
scription factors are underlined.416 Transcriptional Regulation of Human BLT Gene
the BLT1 gene. To determine the methylation state at
these CpG sites, Southern blotting was performed using
genomic DNAs from various cell lines. Although both
MspI and HpaII recognize and digest 59-CCGG-39 se-
quences, MspI but not HpaII can cleave these sequences
when the second cytosine residue is methylated. Capitaliz-
ing on this difference, methylation in the promoter region
was detected. Using probe A, a 59 flanking region of the
promoter, a band of 1.1 kb was detected by MspI digestion
in all the cells examined (Fig. 5 A). However, this band of
1.1 kb was detected only in HL-60 and U937 cells by
HpaII digestion, whereas a partial digested band of 2.5 or
5.5 kb was detected in HL-60, U937, and THP-1 cells or
HL-60 cells, respectively. In HeLa and HepG2 cells, nei-
ther the 1.1 kb nor the 2.5 kb band was observed, whereas
longer bands (z3.0 kb and 7.0 kb, respectively) were de-
tected (Fig. 5 A). Similar results were observed in Southern
blotting using probe B, a sequence 39 to the promoter re-
gion (Fig. 5 B). Considering the size of the detected bands,
the region surrounding the BLT1 promoter is not meth-
ylated in U937 and THP-1 cells, and is almost completely
methylated in HeLa and HepG2 cells. In HL-60 cells (both
Figure 3. Serial deletion mutant analysis
of the BLT1 promoter. Promoter activities
are shown as the luciferase activity relative to
that of the pGL3 basic vector (a promoterless
vector). The activities of THP-1 cells (white
bars) and HeLa cells (black bars) are shown
as the mean 6 SD from three independent
experiments performed in triplicate.
Figure 4. Sp1 binds and activates the BLT1 promoter. (A) EMSAs were performed with 32P-labeled 276/233 using nuclear extracts prepared from
THP-1 and HeLa cells. Two DNA–protein complexes were detected in both cells (lanes 2 and 8; shown as b and c). They were competed by 200-fold
molar excess of unlabeled 276/233 (276/233 WT, lanes 3 and 9), and not by 200-fold molar excess of unlabeled 276/233 with mutations in the GC
box (252/247) (276/233 Sp1 m, lanes 4 and 10). The band b was supershifted by incubation with 1 mg of anti-Sp1 antibody (lanes 6 and 12; shown
as a) but not by the control IgG (lanes 5 and 11). (B) The effect of mutagenesis of Sp1 binding site on the promoter activities. Luciferase activities of the
wild-type construct, p(2123/191) (white columns) and the construct mutated at GC box (black columns) are indicated as mean 6 SD from three inde-
pendent experiments performed in triplicate. Mutation sites are shown in bold at right.417 Kato et al.
differentiated and nondifferentiated), this region appears to
be partially methylated. Northern blotting of these cell
lines showed that HL-60, U937, and THP-1 cells express
BLT1 mRNA, whereas HeLa and HepG2 cells do not
(Fig. 5 D). These results led us to the conclusion that meth-
ylation inhibits BLT1 transcription. Thus, the effect of meth-
ylation on the promoter activity was investigated. The in-
sert of p(2123/191) was treated with SssI methylase,
which methylates cytosine residues at the CpG sites, and a
luciferase assay was performed. The activity of methylated
construct was decreased to z15% of that of the unmeth-
ylated construct (Fig. 6), supporting the conclusion that
methylation of the CpG sites inhibits the BLT1 promoter
activity.
Discussion
LTB4 is a potent activator of granulocytes, eosinophils,
and macrophages. The biological activities of LTB4 are
comparable to those of IL-8 and FMLP, so-called “classical
chemoattractants” (25). LTB4 is unique because it is a lipid
mediator biosynthesized from membrane phospholipids by
the actions of phospholipase A2 (26, 27), 5-lipoxygenase,
and LTA4 hydrolase (2, 28). The actions of LTB4 are be-
lieved to be mediated by a specific cell surface receptor,
BLT (29). Mice overexpressing human BLT1 (originally
termed BLT) showed enhanced granulocyte accumulation
in skin microabscesses and lungs after ischemia reperfusion
induced tissue injury (30), confirming the pathophysiologi-
cal importance of LTB4 in vivo.
Figure 5. Methylation of CpG sites in the
BLT1 promoter region. (A and B) Genomic
DNAs isolated from various cell lines were di-
gested with HpaII or MspI, followed by diges-
tion with EcoRI. The digested DNAs were elec-
trophoresed in 1% agarose gels, transferred to
nylon membranes, and blotted with (A) probe A
and (B) probe B. The positions of the probes A
and B are shown in C. HL-60 (RA) means HL-
60 cells differentiated by 1 mM retinoic acid for
48 h. (C) Methylation sites and genomic organi-
zation. (D) Northern blotting of various cells for
BLT1 ORF. 3 mg of poly(A)1 RNA was used
for each lane.
Figure 6. Effect of the methylation at CpG sites on the promoter activ-
ity. The insert of p(2123/191) was incubated with or without SssI meth-
ylase, ligated into pGL3 basic vector, and transfected into HeLa cells. The
relative luciferase activities are shown as mean 6 SD from three indepen-
dent experiments performed in triplicate.418 Transcriptional Regulation of Human BLT Gene
The cDNA cloning of an LTB4 receptor, BLT1, showed
that BLT1 is a GPCR with seven transmembrane domains
with few similarities to known receptors, including those
for chemoattractants and prostanoids (10). We and others
have successfully cloned cDNA and genomic DNAs of
BLT1 from other species, including mouse (11, 12), guinea
pig (14, 15), and rat (13), and have shown that the primary
structures of BLT1 are conserved among species especially
in the TM domains. BLT1 isolated from various animals
showed subnanomolar Kd values for 3H–LTB4 in transfec-
tion studies, and the binding was inhibited by a number of
specific BLT antagonists. Therefore, BLT1 is a high-affin-
ity receptor for LTB4. The distribution of BLT1 is re-
stricted, with expression observed almost exclusively in pe-
ripheral leukocytes (10, 14), activated macrophages (13),
and eosinophils (11).
In this manuscript, genomic structure, characterization
of the promoter region, and mechanism of cell-specific
transcription of the BLT1 gene are reported. The BLT1
gene consists of three exons, and the ORF is intronless like
other receptors for chemoattractants such as FMLP (31),
IL-8 (32), and platelet-activating factor (PAF [33]).
Owman et al. (9) have shown that the human BLT1 gene
is localized in 14q11.2-q12. Three transcription initiation
sites were detected by 59 RACE analysis when the primer
specific to the 59 UTR of HL-5 clone was used, and these
sites were scattered over 120 bp. There are no TATA or
CAAT elements around these initiation sites, but one of
initiation sites is highly homologous to the initiator se-
quence. The initiator sequence has been reported to play a
role in transcription initiation of various genes (19, 33). No
transcription initiation site was detected using the primer
specific to the 59 UTR of HL-1 clone. Two human BLT1
cDNAs, HL-1 and HL-5, were isolated, and were shown
to share the same ORF, but different 59 UTRs (34). In
Northern blotting of HL-60 and U937 cells, the probe
containing the 59 UTR specific to HL-5 clone gave posi-
tive signals of z1.6 kb and 3.0 kb (data not shown), which
were similar to the results from the probe of the entire
ORF (Fig. 5 D; reference 10). In contrast, the probe con-
taining the 59 UTR specific to HL-1 clone gave no signals
on the same membrane (data not shown), suggesting that
HL-5 and not HL-1 is the major transcript of BLT1, at
least in HL-60 and U937 cells.
We next examined the BLT1 promoter activity using
the 59 flanking region–luciferase fusion plasmids. The re-
sults from various truncated mutants showed that the re-
gion between 276 and the initiator sequence is required
for the basal transcription of the human BLT1 gene. EMSA
analysis revealed that Sp1 binds to 252/247 of the BLT1
promoter. By introducing the mutation at this Sp1 binding
site in p(2123/191), the promoter activity was decreased
to z25% of the wild-type. These results clearly indicate
that Sp1 is important for the basal transcription of the hu-
man BLT1 gene. In the promoter of several myeloid-spe-
cific genes such as CD11b (35), CD18 (36), and hemato-
poietic cell kinase genes (37), Sp1 was reported to act as a
major activator. Although Sp1 is a ubiquitous transcription
factor, it is preferentially expressed in hematopoietic cells
(38). It is still undetermined how Sp1 mediates the tissue-
specific transcription. In our study, significant basal pro-
moter activity was observed in HeLa cells, which do not
express BLT1 intrinsically. EMSA showed that Sp1 binds
to the BLT1 promoter using nuclear extracts from HeLa
cells, and mutagenesis in this Sp1 binding site abolished the
promoter activity in HeLa cells, as observed in the case of
THP-1 cells. Therefore, Sp1 binding to the BLT1 pro-
moter clearly can not explain the tissue- and cell-specific
expression of BLT1. The promoter analysis of l-histidine
decarboxylase (39) and leukosialin (CD43 [reference 40])
genes revealed that Sp1 is a major activator for their tran-
scription. The methylation of their promoter regions at
CpG sites plays an important role in cell- and tissue-specific
transcription. As the promoter region of BLT1 gene has
high CpG contents with Sp1 as a major activator, we stud-
ied the methylation state of the region surrounding the
BLT1 promoter in BLT1-expressing and -nonexpressing
cells.
Genomic Southern blotting was performed to investigate
the methylation state in various cell lines. BLT1-expressing
cells showed the shorter positive bands by digestion with
HpaII, which can cleave only unmethylated CCGG se-
quences. In contrast, HeLa and HepG2 cells, which do not
express BLT1, exhibited the longer digested bands by
HpaII. This implies the significant correlation between the
expression of BLT1 and the methylation state. Next, we
methylated the BLT1 promoter construct p(2123/191)
by SssI methylase in vitro, and examined the effect of this
methylation on the promoter activity in HeLa cells. The
methylated construct showed only 15% promoter activity
of the unmethylated construct. These results show that the
cell-specific expression of BLT1 is primarily dependent on
the methylation of the promoter region. However, EMSA
showed that Sp1 binds similarly to methylated and un-
methylated DNA probes (276/233) in THP-1 and HeLa
cells (data not shown). Sp1 is known to bind to the GC
box in a methylation-insensitive manner (41). The methyl–
CpG binding proteins, MeCP1 (42) and MeCP2 (43), have
been reported to interact specifically with methylated DNA
and repress the transcription. These MeCPs might play a
role as a repressor in the BLT1 transcription.
Furthermore, we found another ORF overlapping the
promoter and 59 UTR of the BLT1 gene. This gene has
high homology with BLT1 and encodes a novel GPCR.
We have named this GPCR as BLT2, and have reported
the role as a low-affinity receptor for LTB4 (16). In
prokaryotes, the overlapping of the promoter and ORF has
been reported (44). For example, in Escherichia coli, the pro-
moter of the b-lactamase gene (ampC) is located within the
last structural gene of the fumarate reductase (frd) operon,
and the ampC attenuator served as the terminator for tran-
scription of the frd operon (45). In our case, the expression
pattern of BLT1 and BLT2 is partially overlapped at tissue
level, as observed in Northern blotting (10, 16). However,
the biological significance of the overlapping of the pro-
moter and ORF was not clarified. Further study should be419 Kato et al.
needed to demonstrate the significance of gene organiza-
tion of two related receptors, BLT1 and BLT2. To our
knowledge, this is the first example in mammals that the
ORF localizes within the promoter region of another gene,
so called “promoter in ORF.”
In conclusion, we have determined the genomic struc-
ture of the human BLT1 gene, and have also identified the
transcription initiation sites and the promoter region of this
gene. Sp1 binding to the promoter region was required for
the basal transcription of the BLT1 gene. Although the
precise mechanism of the tissue-specific transcription of the
BLT1 gene is still not clear, we found that the CpG island
of the BLT1 promoter is methylated in the cells that do not
express BLT1, and also that this methylation inhibits BLT1
transcription in vitro. Our findings enhance the under-
standing of how genes are transcribed in a cell- and tissue-
specific manner, and assist the understanding of the patho-
genesis of inflammatory diseases in which LTB4 and LTB4
receptors are involved. In addition, the presence of “pro-
moter in ORF” in the human genome promises to provide
insights into how mammalian genes show flexibility and
complexity in the transcriptional regulation.
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